BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3343891)

  • 1. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
    Jacobsen LB; Putnam JE; Sawick DP; Cassady JM; Morré DJ
    Life Sci; 1988; 42(8):913-8. PubMed ID: 3343891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
    Kensler TW; Jayaram HN; Cooney DA
    Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid.
    Loh E; Kufe DW
    Cancer Res; 1981 Sep; 41(9 Pt 1):3419-23. PubMed ID: 7260907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
    Moore EC
    Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
    Moyer JD; Handschumacher RE
    Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
    [No Abstract]   [Full Text] [Related]  

  • 7. Salvage of circulating pyrimidine nucleosides in the rat.
    Moyer JD; Oliver JT; Handschumacher RE
    Cancer Res; 1981 Aug; 41(8):3010-7. PubMed ID: 7248957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A; Anderson LW; Strong J; Cysyk RL
    J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
    Karle JM; Anderson LW; Dietrick DD; Cysyk RL
    Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C; Vidgen D
    Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
    Grant S; Rauscher F; Jakubowski A; Cadman E
    Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C
    Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues.
    Zaharevitz DW; Grubb MF; Hyman R; Chisena C; Cysyk RL
    J Natl Cancer Inst; 1993 Apr; 85(8):662-6. PubMed ID: 8468725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
    Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
    Moyer JD; Smith PA; Levy EJ; Handschumacher RE
    Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES; Vale K; Williams LJ; Martin DS; Young CW
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
    Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
    Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells.
    Tsuboi KK; Edmunds NH; Kwong LK
    Cancer Res; 1977 Sep; 37(9):3080-7. PubMed ID: 884665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis.
    Bhalla K; Grant S
    Cancer Chemother Pharmacol; 1987; 19(3):226-32. PubMed ID: 3581416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.